Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial)

J, Ji; Shen, Lei; Li, Z.; Zhang, X.; Han, Liang; Xue, Yuting; Wang, Y.; Zhou, Zhiyuan; Yu, Jing-xin; Chen, L.; Du, Ye; Li, G.; Xiao, Guang‐Qian; Wu, Depei; Zhou, Yu; Dang, CT; He, Yuewen; Zhang, Z.; Sun, Yan; Li, Y.

doi:10.1093/annonc/mdz394.033

Cited by 35 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DFS after D2 gastrectomy, 16 confirming the results of the present study, which was carried out in a real-world setting.…”

Section: Discussionsupporting

confidence: 91%

“…10 The results of the RESOLVE trial were announced at the ESMO Annual Meeting in 2019. 16 This was a phase III clinical study initiated in China and carried out in pathologically confirmed patients with adenocarcinoma of the stomach or gastroesophageal junction. The participants were randomized to 8 cycles of adjuvant XELOX, 8 cycles of adjuvant SOX, and 3 cycles of neoadjuvant SOX.…”

Section: Discussionmentioning

confidence: 99%

“…15 A Phase III trial of XELOX vs SOX after D2 gastrectomy suggested that both regimens could achieve similar DFS. 16 Another study examined the efficacy of adjuvant SOX vs XELOX after D2 gastrectomy for stage III GC, and showed that both regimens achieved similar benefits, but highlighted that additional data are needed in subgroups of patients, especially regarding sex and histological type. 17 Therefore, the aim of this study was to compare the prognosis of patients who received adjuvant SOX vs XELOX in GC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients</p>

Yu¹,

Wang²,

Cheng³

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: To compare the prognosis of adjuvant SOX (S-1 and oxaliplatin) vs XELOX (capecitabine and oxaliplatin) chemotherapy in Chinese patients with gastric cancer (GC) after D2 gastrectomy. Methods: This was a real-world study of patients with GC (stages II-III) who underwent D2 gastrectomy and received adjuvant SOX or XELOX between 01/2010 and 06/2017 in Zhongshan Hospital affiliated to Fudan University. The patients were matched by propensity score matching. The primary and secondary endpoints were disease-free survival (DFS) and overall survival (OS), respectively. Adverse events (AEs) were compared. Results: A total of 552 patients were included. The median follow-up time was 24.9 months. There were no differences in DFS (median, 44.4 vs 41.2 months; HR=1.17, 95% CI: 0.92-1.48) and OS (median, 61.5 vs 65.3 months; HR=1.01, 95% CI: 0.73-1.39) between the XELOX and SOX groups. Both DFS and OS had no significant differences between SOX and XELOX for all subgroups based on sex (P=0.949, P=0.990), age (P=0.303, P=0.392), Lauren type (P=0.362, P=0.573), type of gastrectomy (P=0.607 P=0.989), and pathological TNM stage (P=0.899, P=0.888). A total of 86 patients in the SOX subgroup (34.2%) experienced AEs, similar to the rate found in the XELOX subgroup (104 patients or 41.4%; P=0.098). Discussion: The results suggested that adjuvant SOX chemotherapy has similar survival benefits compared to XELOX chemotherapy in Chinese patients with pathological stage II or III GC after D2 gastrectomy.

show abstract

“…DFS after D2 gastrectomy, 16 confirming the results of the present study, which was carried out in a real-world setting.…”

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients</p>

Yu¹,

Wang²,

Cheng³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…At present, the guidelines in Europe and the USA recommend D1 resection, with D2 resection being an option that should be used sparingly and only by expert surgeons in specialized and high-volume centers [39,40]. The reported frequencies of patients receiving D2 gastrectomy for resectable GC in clinical trials of adjuvant therapy were 10-55% in the West [41][42][43] and 98-100% in the East [44][45][46][47][48][49][50] (Table 1). The 5-year OS rate of patients receiving curative gastrectomy without adjuvant treatment was reported at approximately 70% in Japanese and Korean trials [51,52] and 23-35% in Western trials [36,41,42].…”

Section: Differences In Surgical Outcomes Between Eastern and Westernmentioning

confidence: 99%

“…In the Korean PRODIGY trial, peri-operative chemotherapy consisting of pre-operative DOS (docetaxel, oxaliplatin, and S-1) and post-operative S-1 showed longer progression-free survival (PFS, primary endpoint) over post-operative S-1 in cT2/3-LN-positive or cT4 resectable GC [49]. In the Chinese RESOLVE trial, peri-operative SOX significantly improved DFS compared to post-operative CAPOX in cT4a-LN-positive or cT4b-resectable GC [50] (Table 1).…”

Section: The Standard Treatment In the East Asiamentioning

confidence: 99%

Recent Developments of Systemic Chemotherapy for Gastric Cancer

Arai

Nakajima

2020

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is a molecularly heterogeneous disease. Its molecular background, epidemiology, and standard of care are quite different between Eastern and Western countries. Many efforts have been made in developing more effective surgeries and adjuvant chemotherapies for resectable GC in each region. Recently, an intensive combination of cytotoxic agents has been established as a new standard of adjuvant treatment. Meanwhile, palliative chemotherapy is a uniform standard treatment for unresectable GC worldwide. Recently, one of the most remarkable advances in therapy for unresectable GC has been the approval of immune checkpoint inhibitors (ICIs). The use of ICIs as frontline treatment is currently being investigated. In addition, novel combinations of ICIs and targeted drugs are being evaluated in clinical trials. Despite these advances, the complex biology of GC has resulted in the failure of targeted therapies, with the exceptions of HER2-targeted trastuzumab and VEGFR2-targeted ramucirumab. GC harbors many redundant oncogenic pathways, and small subsets of tumors are driven by different specific pathways. Therefore, a combination strategy simultaneously inhibiting several pathways and/or stricter patient selection for better response to targeted drugs are needed to improve clinical outcomes in this field.

show abstract